Critically, EGFR contributes to the accelerated proliferation of tumor cells and promotes angiogenesis, rendering it an optimal target for targeted NSCLC therapy (Zhou et al., 2020). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.